Phase I/II trial of heat shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent high grade glioma.
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Vitespen (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 17 Sep 2013 Status changed from active, no longer recruiting to completed based on information reported in an Agenus media release.
- 17 Sep 2013 Final results are expected to be published in a scientific journal in 2014 according to an Agenus media release.
- 01 May 2013 Final trial results of this study are expected to be published in a scientific journal in 2013, according to an Agenus media release.